Overview

Study of FTY720 in Patients With Uveitis

Status:
Withdrawn
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride